early RA
RA symptoms
immune tolerance
major proportion of RA patients
immune effects
early phases of RA development
onset of joint inflammation
immune-mediated diseases
specific immune reactions
sub-clinical stages of joint inflammation
clinical trials
onset of disease
immune tolerising treatments of subjects
tolerising therapies
Cure
individuals
defined stages
high risk
disease progress
aim
unexplored phase of disease
bone loss
improved therapies
prevention of diseases
Rheuma Tolerance
new methods
fatigue cause major loss of life quality
IMI2 goals
expansion of pathogenic autoimmune responses
line
precision medicine
maturation
pain
undifferentiated arthritis
successful interference
way
arthralgia
tools
long-lasting therapeutic effect
stratified patient groups
pharma companies
panel of biomarkers
standardisation
better understanding
SMEs
collaboration
experiences
progression
company
proposal
cohorts suitable
work
purposes
protocols
drugs
proposed project
ambition
Investigator